Evidence map›Paper›PMID 36365245›Full record

ReviewPharmaceutics2022

pH-Sensitive Targeting of Tumors with Chemotherapy-Laden Nanoparticles: Progress and Challenges.

Zuha Imtiyaz, Jiaxi He, Qixin Leng, Atul K Agrawal, A James Mixson

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Polymeric Nanocarriers with pH-Dependent Release for Tumor-Specific Delivery.Recent advances in drug delivery and formulation · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zuha ImtiyazDepartment of Pathology, University Maryland School of Medicine, 10 S. Pine St., University of Maryland, Baltimore, MD 21201, USA.
Jiaxi He20511 Seneca Meadows Pkwy, Suite 260, RNAimmune, Germantown, MD 20876, USA.ORCID 0000-0003-2726-6629
Qixin LengDepartment of Pathology, University Maryland School of Medicine, 10 S. Pine St., University of Maryland, Baltimore, MD 21201, USA.
Atul K AgrawalDepartment of Pathology, University Maryland School of Medicine, 10 S. Pine St., University of Maryland, Baltimore, MD 21201, USA.
A James MixsonDepartment of Pathology, University Maryland School of Medicine, 10 S. Pine St., University of Maryland, Baltimore, MD 21201, USA.ORCID 0000-0002-1717-5400
University of Maryland, Baltimore · US

Funding

Developing nanoplexes for RNAi-expressing plasmidsR01EB028534 · NIBIB · UNIVERSITY OF MARYLAND BALTIMORE · PI MIXSON, ARCHIBALD JAMES · 2019 to 2023
$1.4M
NIBIB NIH HHS R01 EB028534NIH HHS R01-EB028534
6 · The paper itself

Abstract

Accumulating chemotherapeutic drugs such as doxorubicin within a tumor while limiting the drug dose to normal tissues is a central goal of drug delivery with nanoparticles. Liposomal products such as Doxil

Indexed as

doxorubicinhistidineimidazolemicellesnanoparticlespolymerstumor pH

Identifiers

PMID36365245
PMCPMC9692785
OpenAlexW4308775188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.